GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (NAS:ROIV) » Definitions » Return-on-Tangible-Equity

Roivant Sciences (Roivant Sciences) Return-on-Tangible-Equity : 604.24% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Roivant Sciences's annualized net income for the quarter that ended in Dec. 2023 was $20,384.7 Mil. Roivant Sciences's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $3,373.6 Mil. Therefore, Roivant Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 604.24%.

The historical rank and industry rank for Roivant Sciences's Return-on-Tangible-Equity or its related term are showing as below:

ROIV' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -75.59   Med: -48.93   Max: 239.22
Current: 239.22

During the past 3 years, Roivant Sciences's highest Return-on-Tangible-Equity was 239.22%. The lowest was -75.59%. And the median was -48.93%.

ROIV's Return-on-Tangible-Equity is ranked better than
97.87% of 1314 companies
in the Biotechnology industry
Industry Median: -47.585 vs ROIV: 239.22

Roivant Sciences Return-on-Tangible-Equity Historical Data

The historical data trend for Roivant Sciences's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Return-on-Tangible-Equity Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23
Return-on-Tangible-Equity
-45.01 -48.93 -75.59

Roivant Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -153.91 -14.76 -131.26 -154.72 604.24

Competitive Comparison of Roivant Sciences's Return-on-Tangible-Equity

For the Biotechnology subindustry, Roivant Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roivant Sciences's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Return-on-Tangible-Equity falls into.



Roivant Sciences Return-on-Tangible-Equity Calculation

Roivant Sciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Mar. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Mar. 2023 )  (A: Mar. 2022 )(A: Mar. 2023 )
=-1009.03/( (1656.944+1012.885 )/ 2 )
=-1009.03/1334.9145
=-75.59 %

Roivant Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=20384.736/( (807.913+5939.348)/ 2 )
=20384.736/3373.6305
=604.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Roivant Sciences  (NAS:ROIV) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Roivant Sciences Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Roivant Sciences (Roivant Sciences) Business Description

Traded in Other Exchanges
Address
50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
Executives
Eric Venker officer: President & COO C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Keith S Manchester director C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Daniel Allen Gold director 6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119
Qvt Financial Lp 10 percent owner, other: Director by Deputization 888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106
Svf Investments (uk) Ltd 10 percent owner 69 GROSVENOR STREET, LONDON X0 W1K3JP
Rakhi Kumar officer: Chief Accounting Officer C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Performance Llc 10 percent owner 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Sumitomo Chemical Co., Ltd. 10 percent owner 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Softbank Vision Fund L.p. 10 percent owner AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Richard Pulik officer: CFO SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB
Vivek Ramaswamy director C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000

Roivant Sciences (Roivant Sciences) Headlines

From GuruFocus

Top 5 4th Quarter Trades of QVT Financial LP

By GuruFocus Research GuruFocus Editor 02-18-2023

Andreas Halvorsen's Firm Curbs Roivant Sciences Stake

By Sydnee Gatewood 06-27-2023